• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Rockwell Medical Inc.

    2/23/23 5:11:57 PM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RMTI alert in real time by email
    SC 13G 1 ea174093-13grich_rockwell.htm SCHEDULE 13G

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934
    (Amendment No. )*

     

    Rockwell Medical, Inc.

     

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

     

    (Title of Class of Securities)

     

    774374300

     

    (CUSIP Number)

     

    DAVID S. RICHMOND

    RICHMOND BROTHERS, INC.

    3568 Wildwood Avenue

    Jackson, Michigan 49202

    (517) 435-4040

     

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

     

    August 15, 2022

     

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☒Rule 13d-1(b)

     

    ☒Rule 13d-1(c)

     

    ☐Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 774374300   13G    

     

    1. NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Richmond Brothers, Inc.
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)   ☒
    (b)   ☐
    3. SEC USE ONLY
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    MICHIGAN

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
      5. SOLE VOTING POWER
     
    5,570
      6. SHARED VOTING POWER
     
    0
      7. SOLE DISPOSITIVE POWER
     
    5,570
      8. SHARED DISPOSITIVE POWER
     
    514,410

    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    519,980
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ☐
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    4.47%1
    12. TYPE OF REPORTING PERSON (see instructions)

    IA, CO

     

    2

     

     

    CUSIP No. 774374300   13G    

     

    1. NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    RBI Private Investment I, LLC
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)   ☒
    (b)   ☐
    3. SEC USE ONLY
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    DELAWARE

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH

    REPORTING
    PERSON WITH

      5. SOLE VOTING POWER
     
    5,894
      6. SHARED VOTING POWER
     
    0
      7. SOLE DISPOSITIVE POWER
     
    5,894
      8. SHARED DISPOSITIVE POWER
     
    0

    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    5,894
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ☐
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    Less than 1%1
    12. TYPE OF REPORTING PERSON (see instructions)

    OO

     

    3

     

     

    CUSIP No. 774374300   13G    

     

    1. NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    RBI Private Investment II, LLC
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)   ☒
    (b)   ☐
    3. SEC USE ONLY
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    DELAWARE

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
      5. SOLE VOTING POWER
     
    3,498
      6. SHARED VOTING POWER
     
    0
      7. SOLE DISPOSITIVE POWER
     
    3,498
      8. SHARED DISPOSITIVE POWER
     
    0

    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,498
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ☐
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    Less than 1%1
    12. TYPE OF REPORTING PERSON (see instructions)

    OO

     

    4

     

     

    CUSIP No. 774374300   13G    

     

    1. NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    The RBI Opportunities Fund I, LLC
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)   ☒
    (b)   ☐
    3. SEC USE ONLY
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    DELAWARE

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
      5. SOLE VOTING POWER
     
    315,073
      6. SHARED VOTING POWER
     
    0
      7. SOLE DISPOSITIVE POWER
     
    315,073
      8. SHARED DISPOSITIVE POWER
     
    0

    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    315,073
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ☐
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    2.7%1
    12. TYPE OF REPORTING PERSON (see instructions)

    OO

     

    5

     

     

    CUSIP No. 774374300   13G    

     

    1. NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    The RBI Opportunities Fund II, LLC
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)   ☒
    (b)   ☐
    3. SEC USE ONLY
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    DELAWARE

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
      5. SOLE VOTING POWER
     
    130,300
      6. SHARED VOTING POWER
     
    0
      7. SOLE DISPOSITIVE POWER
     
    130,300
      8. SHARED DISPOSITIVE POWER
     
    0

    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    130,300
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ☐
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    1.1%1
    12. TYPE OF REPORTING PERSON (see instructions)

    OO

     

    6

     

     

    CUSIP No. 774374300   13G    

     

    1. NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Richmond Brothers 401(k) Profit Sharing Plan
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)   ☒
    (b)   ☐
    3. SEC USE ONLY
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    MICHIGAN

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
      5. SOLE VOTING POWER
     
    11,371
      6. SHARED VOTING POWER
     
    0
      7. SOLE DISPOSITIVE POWER
     
    11,371
      8. SHARED DISPOSITIVE POWER
     
    0

    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    11,371
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ☐
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    Less than 1%1
    12. TYPE OF REPORTING PERSON (see instructions)

    EP

     

    7

     

     

    CUSIP No. 774374300   13G    

     

    1. NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    David S. Richmond
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)   ☒
    (b)   ☐
    3. SEC USE ONLY
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    USA

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
      5.

    SOLE VOTING POWER

     
    476,634

      6. SHARED VOTING POWER

    0
      7. SOLE DISPOSITIVE POWER
     
    476,634
      8. SHARED DISPOSITIVE POWER
     
    514,410

    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    991,044
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ☐
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    8.52% 1
    12. TYPE OF REPORTING PERSON (see instructions)

    IN

     

    8

     

     

    CUSIP No. 774374300   13G    

     

    1. NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Matthew J. Curfman
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)   ☒
    (b)   ☐
    3. SEC USE ONLY
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    USA

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
      5. SOLE VOTING POWER
     
    479,989
      6. SHARED VOTING POWER
     
    0
      7. SOLE DISPOSITIVE POWER
     
    479,989
      8. SHARED DISPOSITIVE POWER
     
    514,410

    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    994,399
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ☐
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    8.55% 1
    12. TYPE OF REPORTING PERSON (see instructions)

    IN

     

    9

     

     

    CUSIP No. 774374300   13G    

     

    Preliminary Statement:

     

    This Schedule 13G is filed by Richmond Brothers, Inc. (“Richmond Brothers”) and amends, supplements and replaces in its entirety the Schedule 13D filed on February 21, 2017, as amended on March 28, 2019 (the “Schedule 13D”), by the Filers, RBI Private Investment I, LLC (“RBI PI”), RBI Private Investment II, LLC (“RBI PII”), The RBI Opportunities Fund, LLC (“RBI Opportunities”), The RBI Opportunities Fund II, LLC (“RBI Opportunities II”), Richmond Brothers 401(k) Profit Sharing Plan (“RBI Plan”), David S. Richmond, and Matthew J. Curfman (collectively, the “Reporting Persons”), relating to shares of Common Stock of Rockwell Medical, Inc. (the “Issuer”). The Schedule 13D had superseded a Schedule 13G previously filed by Richmond Brothers on February 9, 2012 relating to the Common Stock of the Issuer. As part of the dilution of the Common Stock of the Issuer (which commenced on August 15, 2022), the Reporting Persons determined that they no longer hold any shares of Common Stock of the Issuer with any purpose, or with the effect of, changing or influencing control of the Issuer or in connection with or as a participant in any transaction having that purpose or effect. In accordance with Rule 13d-1(h), the Filers accordingly determined to again report their beneficial ownership of shares of Common Stock of the Issuer on Schedule 13G.

     

    Item 1.

     

    (a)Name of Issuer
    Rockwell Medical, Inc

     

    (b)Address of Issuer’s Principal Executive Offices
    30142 S. Wixom Road, Wixon, Michigan 48393

     

    Item 2.

     

      (a)

    Name of Person Filing

     

    Richmond Brothers, Inc., a Michigan corporation (“Richmond Brothers”), which serves as the investment advisor to certain managed accounts (the “Separately Managed Accounts”);

     

    RBI Private Investment I, LLC, a Delaware limited liability company (“RBI PI”);

     

    RBI Private Investment II, LLC, a Delaware limited liability company (“RBI PII”);

     

    The RBI Opportunities Fund, LLC, a Delaware limited liability company (“RBI Opportunities”);

     

    The RBI Opportunities Fund II, LLC, a Delaware limited liability company (“RBI Opportunities II”);

     

    Richmond Brothers 401(k) Profit Sharing Plan, an employee benefit plan organized under the laws of

    Michigan (the “RBI Plan”);

     

    David S. Richmond, who serves as Chairman of Richmond Brothers, manager of RBI Manager and a trustee of the RBI Plan; and

     

    Matthew J. Curfman, who serves as President of Richmond Brothers and a trustee of the RBI Plan

     

    10

     

     

    CUSIP No. 774374300   13G    

     

      (b) Address of the Principal Office or, if none, residence
    3568 Wildwood Avenue, Jackson, Michigan 49202
         
      (c) Citizenship
    United States of America
         
      (d) Title of Class of Securities
    Common Stock, par value $0.0001 (“Shares”)
         
      (e) CUSIP Number
    774374300

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
           
      (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) ☒ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
           
      (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

    Item 4. Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a) Amount beneficially owned: 999, 327

     

      (b) Percent of class:

    The Common Shares beneficially owned by the Filers constitute approximately 8.59% of the 11,632,673 issued and outstanding Common Shares s reported in the Form 10-Q filed by the Issuer with the Securities and Exchange Commission for the quarter ending November 14, 2022.

     

    11

     

     

    CUSIP No. 774374300   13G    

     

      (c) Number of shares as to which the person has:
             
      (i) Sole power to vote or to direct the vote of 0

     

        (ii) Shared power to vote or to direct the vote of 999,327

     

        (iii) Sole power to dispose or to direct the disposition of 0  

      

        (iv) Shared power to dispose or to direct the disposition of 999,327

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Instruction. Dissolution of a group requires a response to this item.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Item 9. Notice of Dissolution of Group.

     

    Item 10. Certification.

     

      (a) The following certification shall be included if the statement is filed pursuant to §240.13d-1(b):
         
        By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
         
      (b) The following certification shall be included if the statement is filed pursuant to §240.13d-1(c):
         
        By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    12

     

     

    CUSIP No. 774374300   13G    

     

    SIGNATURES

     

    After reasonable inquiry and to the best of his knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: February 23, 2023

      

    Richmond Brothers, Inc.  
         
    By: /s/ David S. Richmond  
      Name:  David S. Richmond  
      Title: Chairman  

     

    RBI Private Investment I, LLC  
       
    By: RBI PI Manager, LLC  
      Manager  
         
    By: /s/ David S. Richmond  
      Name:  David S. Richmond  
      Title: Manager  

     

    RBI Private Investment II, LLC  
       
    By: RBI PI Manager, LLC  
      Manager  
         
    By: /s/ David S. Richmond  
      Name:  David S. Richmond  
      Title: Manager  

     

    The RBI Opportunities Fund, LLC  
       
    By: RBI PI Manager, LLC  
      Manager  
         
    By: /s/ David S. Richmond  
      Name:  David S. Richmond  
      Title: Manager  

     

    13

     

     

    CUSIP No. 774374300   13G    

     

    The RBI Opportunities Fund II, LLC  
       
    By: RBI PI Manager, LLC  
      Manager  
         
    By: /s/ David S. Richmond  
      Name:  David S. Richmond  
      Title: Manager  

     

    By: RBI PI Manager, LLC  
         
    By: /s/ David S. Richmond  
      Name:  David S. Richmond  
      Title: Manager  

     

    By: Richmond Brothers 401(k) Profit Sharing Plan  
         
    By: /s/ David S. Richmond  
      Name:  David S. Richmond  
      Title: Trustee  

     

      /s/ David S. Richmond  
      David S. Richmond  
         
      /s/ Matthew J. Curfman  
      Matthew J. Curfman  

     

     

    14

     

     

     

    Get the next $RMTI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RMTI

    DatePrice TargetRatingAnalyst
    11/14/2024$5.00Buy
    Rodman & Renshaw
    1/18/2022$5.00 → $3.00Buy
    HC Wainwright & Co.
    9/7/2021$5.50 → $5.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $RMTI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rockwell Medical Announces First Quarter 2025 Results

      Reports net sales of $18.9 million for the first quarter of 2025, a 17% decrease from net sales of $22.7 million for the first quarter of 2024. Reports gross profit of $3.0 million for the first quarter of 2025, in line with the same period in 2024. Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three months ended March 31, 2025. "During the first quarter, we continued to diversify our customer base with some of the leading regional, national and global hemodialysis provi

      5/12/25 6:00:00 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rockwell Medical to Release First Quarter 2025 Results on Monday, May 12, 2025

      Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the first quarter ended March 31, 2025 on Monday, May 12, 2025. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET. CONFERENCE CALL AND WEBCAST DETAILS Date: Monday, May 12, 2025 Time: 8:00am ET Live Number: (888) 660-6347 // (International) 1 (929) 201-6594 Conference Call ID: 4944610 Webcast and Replay: www.RockwellMed.com/Results Speakers:

      4/14/25 6:00:00 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rockwell Medical Announces Fourth Quarter and Full-Year 2024 Financial and Operational Results

      Achieves profitability on an adjusted EBITDA basis for the full-year 2024, the first time in the Company's history. Reports record gross profit for the third year in a row, generating $17.5 million in 2024, a 101% increase over 2023. Reports record net sales for the third year in a row, generating $101.5 million in 2024, a 21% increase over 2023. Net sales for the fourth quarter of 2024 were $24.7 million, a 12% increase over the same period in 2023. Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and o

      3/20/25 6:00:00 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RMTI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Irrevocable Larson Family Investment Trust bought $94,018 worth of shares (87,500 units at $1.07), increasing direct ownership by 3% to 3,557,500 units (SEC Form 4)

      4 - ROCKWELL MEDICAL, INC. (0001041024) (Issuer)

      4/15/25 2:02:44 PM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RMTI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Irrevocable Larson Family Investment Trust bought $94,018 worth of shares (87,500 units at $1.07), increasing direct ownership by 3% to 3,557,500 units (SEC Form 4)

      4 - ROCKWELL MEDICAL, INC. (0001041024) (Issuer)

      4/15/25 2:02:44 PM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Strobeck Mark sold $7,480 worth of shares (6,926 units at $1.08), decreasing direct ownership by 5% to 124,678 units (SEC Form 4)

      4 - ROCKWELL MEDICAL, INC. (0001041024) (Issuer)

      4/2/25 6:06:41 PM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, FINANCE AND CFO Neri Jesse sold $975 worth of shares (886 units at $1.10), decreasing direct ownership by 3% to 30,000 units (SEC Form 4)

      4 - ROCKWELL MEDICAL, INC. (0001041024) (Issuer)

      4/2/25 6:05:02 PM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RMTI
    Leadership Updates

    Live Leadership Updates

    See more
    • Universal Display Corporation Announces the Appointment of New Board Members

      Universal Display Corporation (NASDAQ:OLED) (UDC), enabling energy-efficient displays and lighting with its UniversalPHOLED® technology and materials, today announced that Dr. Nigel Brown and Dr. Joan Lau have joined the Company's Board of Directors, effective March 4, 2024. The addition of these new directors expands UDC's Board to ten members. "I am pleased to welcome Nigel and Joan to the Board," said Steven V. Abramson, President and Chief Executive Officer of Universal Display Corporation and a member of the Board. "Nigel adds a wealth of business innovation, technical knowledge and corporate strategic planning expertise to our Board. Joan brings over two decades of extensive scienti

      3/7/24 4:05:00 PM ET
      $BDN
      $NOTV
      $OLED
      $RMTI
      Real Estate Investment Trusts
      Real Estate
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Rockwell Medical Appoints Joan Lau, Ph.D. to the Company's Board of Directors

      Brings more than 20 years of experience as an entrepreneur scientist, CEO, operator, investor, and board member of public and private biopharmaceutical companies Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company appointed Joan Lau, Ph.D. to its board of directors. Dr. Lau's appointment increases Rockwell Medical's board of directors to seven members. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231017906241/en/RMTI) (Photo: Business Wire)"

      10/17/23 6:00:00 AM ET
      $BDN
      $RMTI
      $RCOR
      Real Estate Investment Trusts
      Real Estate
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rockwell Medical, Inc. Appoints Mark Strobeck, Ph.D., as President and Chief Executive Officer

      WIXOM, Mich. , June 22, 2022 /PRNewswire/ -- Rockwell Medical, Inc. (NASDAQ:RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management, today announced that the Board of Directors has appointed Mark Strobeck, Ph.D., as President and Chief Executive Officer, effective July 1, 2022. Dr. Strobeck will also join the Company's Board of Directors. Russell Ellison, M.D., M.Sc., will be stepping down as President and Chief Executive Officer and as a member of the Company's Board of Directors effective June 30, 2022. "We are exci

      6/24/22 8:56:00 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RMTI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rodman & Renshaw initiated coverage on Rockwell Medical with a new price target

      Rodman & Renshaw initiated coverage of Rockwell Medical with a rating of Buy and set a new price target of $5.00

      11/14/24 7:56:29 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Rockwell Medical with a new price target

      HC Wainwright & Co. reiterated coverage of Rockwell Medical with a rating of Buy and set a new price target of $3.00 from $5.00 previously

      1/18/22 10:00:06 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Rockwell Medical with a new price target

      HC Wainwright & Co. reiterated coverage of Rockwell Medical with a rating of Buy and set a new price target of $5.00 from $5.50 previously

      9/7/21 6:17:47 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RMTI
    SEC Filings

    See more
    • Rockwell Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - ROCKWELL MEDICAL, INC. (0001041024) (Filer)

      5/12/25 7:21:47 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Rockwell Medical Inc.

      10-Q - ROCKWELL MEDICAL, INC. (0001041024) (Filer)

      5/12/25 7:00:44 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rockwell Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ROCKWELL MEDICAL, INC. (0001041024) (Filer)

      5/12/25 6:18:10 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RMTI
    Financials

    Live finance-specific insights

    See more
    • Rockwell Medical Announces First Quarter 2025 Results

      Reports net sales of $18.9 million for the first quarter of 2025, a 17% decrease from net sales of $22.7 million for the first quarter of 2024. Reports gross profit of $3.0 million for the first quarter of 2025, in line with the same period in 2024. Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three months ended March 31, 2025. "During the first quarter, we continued to diversify our customer base with some of the leading regional, national and global hemodialysis provi

      5/12/25 6:00:00 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rockwell Medical to Release First Quarter 2025 Results on Monday, May 12, 2025

      Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the first quarter ended March 31, 2025 on Monday, May 12, 2025. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET. CONFERENCE CALL AND WEBCAST DETAILS Date: Monday, May 12, 2025 Time: 8:00am ET Live Number: (888) 660-6347 // (International) 1 (929) 201-6594 Conference Call ID: 4944610 Webcast and Replay: www.RockwellMed.com/Results Speakers:

      4/14/25 6:00:00 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rockwell Medical Announces Fourth Quarter and Full-Year 2024 Financial and Operational Results

      Achieves profitability on an adjusted EBITDA basis for the full-year 2024, the first time in the Company's history. Reports record gross profit for the third year in a row, generating $17.5 million in 2024, a 101% increase over 2023. Reports record net sales for the third year in a row, generating $101.5 million in 2024, a 21% increase over 2023. Net sales for the fourth quarter of 2024 were $24.7 million, a 12% increase over the same period in 2023. Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and o

      3/20/25 6:00:00 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RMTI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Rockwell Medical Inc.

      SC 13G/A - ROCKWELL MEDICAL, INC. (0001041024) (Subject)

      11/14/24 5:17:40 PM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Rockwell Medical Inc. (Amendment)

      SC 13G/A - ROCKWELL MEDICAL, INC. (0001041024) (Subject)

      2/14/24 2:31:02 PM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Rockwell Medical Inc. (Amendment)

      SC 13D/A - ROCKWELL MEDICAL, INC. (0001041024) (Subject)

      9/6/23 4:49:44 PM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care